{
    "clinical_study": {
        "@rank": "151445", 
        "arm_group": [
            {
                "arm_group_label": "Lesinurad and Metformin", 
                "arm_group_type": "Experimental", 
                "description": "Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg\nSequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
            }, 
            {
                "arm_group_label": "Lesinurad and Furosemide", 
                "arm_group_type": "Experimental", 
                "description": "Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg\nSequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the potential effects of lesinurad on the pharmacokinetics (PK) of\n      metformin and furosemide in healthy, adult male subjects."
        }, 
        "brief_title": "Metformin and Furosemide Drug-Drug Interaction Study", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Leinurad is a weak in vitro inhibitor of the hepatic transporter OCT1 and the renal\n      transporters OAT1 and OAT3 (OAT1/3). To assess the clinical relevance of these in vitro\n      findings, this clinical study will evaluate the effect of lesinurad on the PK of metformin\n      (OCT1 substrate) and furosemide (OAT1/3 substrate)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs) and body mass index \u2265 18 and \u2264 30 kg/m2.\n\n          -  Subject is free of any clinically significant disease or medical condition, per the\n             Investigator's judgment.\n\n        Exclusion Criteria:\n\n          -  Subject has a history or suspicion of kidney stones, prostatic hyperplasia, or\n             urinary stricture.\n\n          -  Subject has undergone major surgery within 3 months prior to Screening.\n\n          -  Subject donated blood or experienced significant blood loss (>450 mL) within 12 weeks\n             prior to Screening or gave a plasma donation within 4 weeks prior to Screening.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028689", 
            "org_study_id": "RDEA594-128"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lesinurad and Metformin", 
                    "Lesinurad and Furosemide"
                ], 
                "intervention_name": "Lesinurad 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad and Metformin", 
                "intervention_name": "Metformin 850 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad and Furosemide", 
                "intervention_name": "Furosemide 40 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Furosemide", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49007"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate Potential Pharmacokinetic Interaction Between Lesinurad and Metformin and Between Lesinurad and Furosemide in Health Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "S. Bradley", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Profile in terms of maximum observed concentration (Cmax), time of occurence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), and apparent terminal half-life (t1/2).", 
                "measure": "PK profile of metformin and furosemide from plasma", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 5"
            }, 
            {
                "description": "Profile in terms of renal clearance (CLr) and amount of compound excreted into urine unchanged (Ae).", 
                "measure": "PK profile of furosemide from urine", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 5"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}